- Home
- KEYS vs ONC Comparison
KEYS vs ONC Comparison
Compare KEYS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEYS
- ONC
- Stock Information
- Founded
- KEYS 1939
- ONC 2010
- Country
- KEYS United States
- ONC Switzerland
- Employees
- KEYS N/A
- ONC N/A
- Industry
- KEYS Industrial Machinery/Components
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- KEYS Industrials
- ONC Health Care
- Exchange
- KEYS Nasdaq
- ONC Nasdaq
- Market Cap
- KEYS 25.9B
- ONC 26.9B
- IPO Year
- KEYS N/A
- ONC N/A
- Fundamental
- Price
- KEYS $160.86
- ONC $251.72
- Analyst Decision
- KEYS Buy
- ONC Strong Buy
- Analyst Count
- KEYS 9
- ONC 7
- Target Price
- KEYS $183.00
- ONC $326.43
- AVG Volume (30 Days)
- KEYS 1.1M
- ONC 364.5K
- Earning Date
- KEYS 05-20-2025
- ONC 05-07-2025
- Dividend Yield
- KEYS N/A
- ONC N/A
- EPS Growth
- KEYS N/A
- ONC N/A
- EPS
- KEYS 4.26
- ONC N/A
- Revenue
- KEYS $5,108,000,000.00
- ONC $4,180,740,829.00
- Revenue This Year
- KEYS $7.43
- ONC $32.78
- Revenue Next Year
- KEYS $6.23
- ONC $19.07
- P/E Ratio
- KEYS $37.76
- ONC N/A
- Revenue Growth
- KEYS N/A
- ONC 52.09
- 52 Week Low
- KEYS $119.72
- ONC $141.31
- 52 Week High
- KEYS $186.20
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- KEYS 55.79
- ONC N/A
- Support Level
- KEYS $155.20
- ONC N/A
- Resistance Level
- KEYS $162.79
- ONC N/A
- Average True Range (ATR)
- KEYS 3.35
- ONC 0.00
- MACD
- KEYS -0.91
- ONC 0.00
- Stochastic Oscillator
- KEYS 18.71
- ONC 0.00
About KEYS Keysight Technologies Inc.
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.